Four recurrent chromosomal translocations, namely t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH, t(14;18)(q32;q21)/IGH-MALT1 and t(3;14)(p13;q32)/FOXP1-IGH, have been described in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). The oncogenic products of the first three translocations are believed to exert their oncogenic activity through activation of the transcription factor NF-kB, whereas the role of FOXP1 in lymphomagenesis remains to be investigated. 1 These translocations occur at variable incidences in MALT lymphomas of different sites, and are rare or absent in the ocular adnexa, salivary glands and thyroid. 1 To characterize the genetic makeup of MALT lymphoma lacking the above chromosomal translocations, we investigated the genomic profiles of translocation negative MALT lymphomas of the ocular adnexa and lung by array-comparative genomic hybridization (array-CGH) and identified A20 as the target of 6q23.3 deletion and TNF locus as a potential target of 6p21 gain exclusively in ocular adnexal cases. 2 Subsequent fluorescence in situ hybridization screening showed that A20 deletion occurred preferentially in MALT lymphomas of the ocular adnexa, salivary glands and thyroid. In ocular adnexal cases, in which clinical information was available, A20 deletion was significantly associated with adverse clinical parameters, and this association was independent of the presence of other genetic abnormalities. 2 Interestingly, among the 12 cases showing A20 deletion, 3 displayed a homozygous deletion, indicating complete inactivation of the gene. While preparing our manuscript, four independent studies reported biallelic inactivation of A20 by mutation and/or deletion in 67/381 (17.5%) B-cell lymphomas, including MALT lymphoma, diffuse large B-cell lymphoma and Hodgkin lymphoma.
3-6 A20, also known as TNF a-induced protein 3 (TNFAIP3), is a well-known negative regulator of the NF-kB activation pathway and can attenuate the NF-kB activity triggered by signaling from TNF and Toll-like receptors. 7 In view of these findings, A20 could potentially act as a tumor suppressor gene. Nonetheless, it remains to be investigated whether A20, like other tumor suppressor genes, is also targeted for inactivation by promoter methylation and whether A20 abnormalities impact on clinical presentation and treatment response. In this study, we investigated A20 genetic and epigenetic abnormalities, and also examined the clinical impact of A20 inactivation in MALT lymphoma.
A total of 17 MALT lymphomas with available adequate DNA samples or tissue materials were screened for mutation in the A20 coding sequence by PCR and sequencing using DNA samples extracted from microdissected tumor cells of formalin-fixed paraffin-embedded tissue biopsies (Supplementary Materials and methods; Supplementary Table S1). They included seven cases showing A20 hemizygous deletion with or without TNF locus gain, four cases with TNF locus gain only and a further six cases without these abnormalities. 2 A total of 4 mutations were detected in 3 (17.6%) of the 17 cases examined. All the mutations were confirmed by sequencing at least two independent PCR products from both orientations and excluded from the known polymorphisms. Cases 9 and 12 showed one nonsense mutation each, whereas case 16 showed one nonsense mutation and a 2 bp deletion (frozen tissue was not available, thus not possible to further investigate whether these mutations occurred in one or both alleles) ( Table 1 ). Case 9 showed both A20 mutation and hemizygous deletion, whereas cases 12 and 16 showed A20 gene mutation but not deletion.
A20 promoter methylation was investigated in a total of 27 MALT lymphomas of the ocular adnexa (25), salivary glands (1) and thyroid (1) (Supplementary Materials and methods). Genomic DNA was treated by bisulfite to convert unmethylated cytosine to uracil, while keeping methylated cytosines intact, and then analyzed by pyrosequencing to assess methylation of 18 consecutive CpG positions in the A20 promoter region. High efficiency of bisulfite treatment was demonstrated by internal conversion controls ( Figure 1 ). The reliability of the assay was further ascertained by reproducible results from independent bisulfite treatments and pyrosequencing experiments. A20 promoter methylation was seen in 7 (26%) of the 27 MALT lymphomas investigated, and they included 5 ocular adnexal cases and both extra-ocular cases (Table 1; Figure 1 ). Of these seven cases, six showed a similar methylation pattern, with prominent methylation at the 7th, 8th and 9th CpG sites. Remarkably, A20 promoter methylation was significantly associated with A20 hemizygous deletion (P ¼ 0.011, Fisher's exact test), being found in 5/8 (62%) cases with hemizygous deletion, but only in 2/19 (11%) cases with an intact A20 ( Table 1) . None of the four cases with A20 promoter methylation, which were also investigated for mutation, showed A20 gene mutation. The single case (no. 9) that harbored both A20 gene deletion and nonsense mutation showed no evidence of A20 promoter methylation. Thus, it appeared that A20 promoter methylation and gene mutation are mutually exclusive. To our knowledge, this is the first comprehensive analysis Letters to the Editor Table 1 A20 abnormalities and clinicopathological correlation in MALT lymphoma The results on A20 and TNF genes copy number changes were obtained from a previous study. Letters to the Editor of A20 promoter methylation by pyrosequencing in lymphoma. While revising our manuscript, Honma et al. reported A20 methylation in 10 of 24 cases of activated B-cell like diffuse large B-cell lymphoma and 3 of 8 cases of mantle cell lymphoma by methylation-specific PCR analysis of a single CpG site upstream of the kB-biding sites. 8 To investigate further the impact of A20 deletion and promoter methylation on its transcript expression, we measured the A20 mRNA expression in cases with adequate tissue materials by real-time quantitative RT-PCR. RNA was extracted from microdissected tumor cells of formalin-fixed paraffinembedded tissues in eight cases (Supplementary Materials and methods; Supplementary Table S2). They included three cases without any A20 abnormalities, one case with hemizygous deletion, three cases with A20 hemizygous deletion and promoter methylation and one case with homozygous A20 deletion. Real-time quantitative RT-PCR was performed with two sets of A20 primers, along with GAPDH and 18S rRNA as reference control. Results from both sets of A20 primers were similar and showed a trend of correlation between the extent of A20 abnormalities and the level of A20 mRNA expression. The lowest expression was seen in the cases with complete A20 inactivation either by homozygous deletion or hemizygous deletion plus promoter methylation, whereas the highest expression was found in the cases with intact A20 (Supplementary Figure S1 ). Although the number of comparable cases allowing direct analysis of the impact of A20 promoter methylation on its transcript expression was small, the cases with both hemizygous deletion and promoter methylation did show a lower A20 transcript expression than the case with only A20 hemizygous deletion. These preliminary results are in line with the expected role of promoter methylation in transcriptional silencing of the remaining A20 allele.
Thus, concurrent A20 hemizygous deletion and promoter methylation or mutation, as well as homozygous A20 deletion, could result in complete A20 gene inactivation, whereas A20 hemizygous deletion or promoter methylation most likely lead to partial A20 inactivation. In keeping with this notion, there was a significant correlation between the extent of A20 abnormalities and clinicopathological presentations in ocular adnexal MALT lymphoma. Clinicopathological data were available in 17 cases (follow-up: 6-242 months, median 30 months, Table 1 ). Most of these patients were treated by radiotherapy. The case (no.16) that harbored two mutations was excluded from clinical correlation analyses, as it was not possible to determine whether the mutations affect one or both alleles, thus define whether A20 was completely or partially inactivated. Both A20 complete and partial inactivation were associated with concurrent involvement of different adnexal tissues or distant spread at diagnosis (P ¼ 0.016, P ¼ 0.047, respectively, Fisher's exact test). Importantly, A20 complete inactivation was significantly associated with a shorter lymphoma-free survival (Po0.001, Figure 2 ), whereas cases with partial inactivation shared a similar Figure 2 Clinical impact of A20 inactivation on lymphoma-free survival in ocular adnexal MALT lymphoma. Kaplan-Meier estimates of lymphoma-free survival according to A20 gene status, using log-rank test for comparison (event 'relapse' right-censored, Statistical Package for Social Sciences SPSS UK version 13). Complete inactivation is defined by the presence of both A20 hemizygous deletion and promoter methylation (three cases), whereas partial inactivation corresponds to the presence of A20 hemizygous deletion (two cases) or promoter methylation (one case) or mutation (one case).
profile to those without A20 abnormalities. Although these findings await confirmation by study of large cohort of cases, the observation highlights for the first time the importance of complete inactivation of the A20 gene in lymphoma development.
Our findings showed, for the first time, that promoter methylation was an alternative mechanism for A20 inactivation in MALT lymphoma, in addition to gene deletion and mutation reported very recently. [3] [4] [5] [6] 8 The biallelic inactivation by promoter methylation and deletion, hemizygous deletion and mutation, homozygous deletion is in line with the Knudson's two-hit hypothesis on the inactivation of tumor suppressor genes. As expected, re-expression of wild-type A20 in cell lines with biallelic inactivation of the A20 gene induced apoptosis and cell growth arrest and these effects depended on its negative regulation of NF-kB pathway. 5, 6, 8 Together, these findings indicate that A20 is a new tumor suppressor in lymphoma. In view of the critical role of A20 as a central negative regulator of NF-kB activation pathway and the diverse functions of NF-kB in B-and T-cell development and biology, the extent of A20 involvement in various lymphoma subtypes remains to be investigated.
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